Skip to main content
Erschienen in: Inflammation Research 6/2020

07.04.2020 | Original Research Paper

LncRNA SNHG5 regulates SOX4 expression through competitive binding to miR-489-3p in acute myeloid leukemia

verfasst von: Xiaoyang Ying, Wanggang Zhang, Meiyun Fang, Chenchen Wang, Li Han, Chenmeng Yang

Erschienen in: Inflammation Research | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Currently, lncRNA plays an important role in the occurrence and development of acute myeloid leukemia (AML), including SNHG5. However, the role and mechanism of SNHG5 in AML remains unclear. In this study, we explored the regulatory mechanism of SNHG5 in the development of AML.

Methods and results

QRT-PCR was used to investigate the expression of SNHG5, miR-489-3p, and SOX. The proliferation and apoptosis of AML cells were analyzed by cell transfection, cell counting kit-8 (CCK8), and flow cytometric analysis. Moreover, the expression analysis of marker proteins was detected by western blot. Through luciferase activity assay, RNA pull-down, and RNA-binding protein immunoprecipitation (RIP), we proved that SNHG5 could bind miR-489-3p and SOX4 which might be the target gene of miR-489-3p.

Results

We first found that SNHG5 was up-regulated in both AML patient bone marrow samples and various AML cell lines. Second, we found that knockdown of SNHG5 inhibited proliferation of AML cells and promoted apoptosis. It was found that SNHG5 could bind miR-489-3p, and the relative expression of SNHG5 was negatively correlated with miR-489-3p. Further results suggested that SOX4 might be the target gene of miR-489-3p. Finally, our experimental data indicated that knockdown of SNHG5 could reduce the tumor volume and down-regulated SOX4 levels in vivo.

Conclusions

Our results demonstrated that SNHG5 affected the expression of SOX4 through binding miR-489-3p to regulate proliferation and apoptosis of AML, which might act as a prospective prognostic biological marker and a promising therapeutic target for AML.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Houda H. Angiogenesis and acute myeloid leukemia. Hematology. 2014;19(6):311–23.CrossRef Houda H. Angiogenesis and acute myeloid leukemia. Hematology. 2014;19(6):311–23.CrossRef
2.
Zurück zum Zitat Grimwade D. The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia. Best Pract Res Clin Haematol. 2001;14(3):497–529.CrossRef Grimwade D. The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia. Best Pract Res Clin Haematol. 2001;14(3):497–529.CrossRef
3.
Zurück zum Zitat Omar AW, Levine RL. Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. Blood. 2013;121(18):3563–72.CrossRef Omar AW, Levine RL. Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. Blood. 2013;121(18):3563–72.CrossRef
4.
Zurück zum Zitat Alessandro I, Valentina S, Marilena C, Federica L, Giuseppe V, Sarah P, et al. The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment. Expert Rev Hematol. 2014;7(6):807–18.CrossRef Alessandro I, Valentina S, Marilena C, Federica L, Giuseppe V, Sarah P, et al. The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment. Expert Rev Hematol. 2014;7(6):807–18.CrossRef
5.
Zurück zum Zitat Ha PM, Cho SA, Kyung Hyun Y, Moon Hee Y, Young AJ, Hyo Soo L, et al. Gene expression profile related to prognosis of acute myeloid leukemia. Oncol Rep. 2007;18(6):1395–402. Ha PM, Cho SA, Kyung Hyun Y, Moon Hee Y, Young AJ, Hyo Soo L, et al. Gene expression profile related to prognosis of acute myeloid leukemia. Oncol Rep. 2007;18(6):1395–402.
6.
Zurück zum Zitat Basturk A, Akinci S, Hacibekiroglu T, Guney T, Kutlucan A, Ceran F, et al. Prognostic significance of flow cytometry findings in Turkish adult acute leukemia patients. Eur Rev Med Pharmacol Sci. 2015;19(18):3360–6.PubMed Basturk A, Akinci S, Hacibekiroglu T, Guney T, Kutlucan A, Ceran F, et al. Prognostic significance of flow cytometry findings in Turkish adult acute leukemia patients. Eur Rev Med Pharmacol Sci. 2015;19(18):3360–6.PubMed
7.
Zurück zum Zitat Yang G, Lu X, Yuan L. LncRNA: a link between RNA and cancer. Biochem Biophys Acta. 2014;1839(11):1097–109.PubMed Yang G, Lu X, Yuan L. LncRNA: a link between RNA and cancer. Biochem Biophys Acta. 2014;1839(11):1097–109.PubMed
8.
Zurück zum Zitat Gibb EA, Brown CJ, Wan LL. The functional role of long non-coding RNA in human carcinomas. Mol Cancer. 2011;10(1):38.CrossRef Gibb EA, Brown CJ, Wan LL. The functional role of long non-coding RNA in human carcinomas. Mol Cancer. 2011;10(1):38.CrossRef
9.
Zurück zum Zitat Fernando TR, Rodriguez-Malave NI, Waters EV, Yan W, Casero D, Basso G, et al. LncRNA expression discriminates karyotype and predicts survival in B-lymphoblastic leukemia. Mol Cancer Res. 2015;13(5):839–51.CrossRef Fernando TR, Rodriguez-Malave NI, Waters EV, Yan W, Casero D, Basso G, et al. LncRNA expression discriminates karyotype and predicts survival in B-lymphoblastic leukemia. Mol Cancer Res. 2015;13(5):839–51.CrossRef
10.
Zurück zum Zitat Chen L, Wang W, Cao L, Li Z, Wang X. Long non-coding RNA CCAT1 acts as a competing endogenous RNA to regulate cell growth and differentiation in acute myeloid leukemia. Mol Cells. 2016;39(4):330–6.CrossRef Chen L, Wang W, Cao L, Li Z, Wang X. Long non-coding RNA CCAT1 acts as a competing endogenous RNA to regulate cell growth and differentiation in acute myeloid leukemia. Mol Cells. 2016;39(4):330–6.CrossRef
11.
Zurück zum Zitat He B, Bai Y, Kang W, Zhang X, Jiang X. LncRNA SNHG5 regulates imatinib resistance in chronic myeloid leukemia via acting as a CeRNA against MiR-205-5p. Am J Cancer Res. 2017;7(8):1704.PubMedPubMedCentral He B, Bai Y, Kang W, Zhang X, Jiang X. LncRNA SNHG5 regulates imatinib resistance in chronic myeloid leukemia via acting as a CeRNA against MiR-205-5p. Am J Cancer Res. 2017;7(8):1704.PubMedPubMedCentral
12.
Zurück zum Zitat Jiang L, He D, Yang D, Chen Z, Pan Q, Mao A, et al. MiR-489 regulates chemoresistance in breast cancer via epithelial mesenchymal transition pathway. FEBS Lett. 2014;588(11):2009–155.CrossRef Jiang L, He D, Yang D, Chen Z, Pan Q, Mao A, et al. MiR-489 regulates chemoresistance in breast cancer via epithelial mesenchymal transition pathway. FEBS Lett. 2014;588(11):2009–155.CrossRef
13.
Zurück zum Zitat Xie Z, Cai L, Li R, Zheng J, Wu H, Yang X, et al. Down-regulation of miR-489 contributes into NSCLC cell invasion through targeting SUZ12. Tumour Biol. 2015;36(8):6497–505.CrossRef Xie Z, Cai L, Li R, Zheng J, Wu H, Yang X, et al. Down-regulation of miR-489 contributes into NSCLC cell invasion through targeting SUZ12. Tumour Biol. 2015;36(8):6497–505.CrossRef
17.
Zurück zum Zitat Press OU. World Medical Association declaration of Helsinki. Gastroenterologia Japonica. 1991;26(2):269–70.CrossRef Press OU. World Medical Association declaration of Helsinki. Gastroenterologia Japonica. 1991;26(2):269–70.CrossRef
18.
Zurück zum Zitat Clark JD, Gebhart GF, Gonder JC, Keeling ME, Kohn DF. The 1996 guide for thecare and use of laboratory animals. Ilar J. 1997;38(1):41–8.CrossRef Clark JD, Gebhart GF, Gonder JC, Keeling ME, Kohn DF. The 1996 guide for thecare and use of laboratory animals. Ilar J. 1997;38(1):41–8.CrossRef
19.
Zurück zum Zitat Shi DB, Wang YW, Xing AY, Gao JW, Zhang H, Guo XY, et al. C/EBPα-induced miR-100 expression suppresses tumor metastasis and growth by targeting ZBTB7A in gastric cancer. Cancer Lett. 2015;369(2):376–85.CrossRef Shi DB, Wang YW, Xing AY, Gao JW, Zhang H, Guo XY, et al. C/EBPα-induced miR-100 expression suppresses tumor metastasis and growth by targeting ZBTB7A in gastric cancer. Cancer Lett. 2015;369(2):376–85.CrossRef
23.
Zurück zum Zitat Liu Q, Yang G, Qian Y. Loss of MicroRNA-489-3p promotes osteosarcoma metastasis by activating PAX3-MET pathway. Mol. Carcinog. 2016;56(4):1312–21.CrossRef Liu Q, Yang G, Qian Y. Loss of MicroRNA-489-3p promotes osteosarcoma metastasis by activating PAX3-MET pathway. Mol. Carcinog. 2016;56(4):1312–21.CrossRef
24.
Zurück zum Zitat Apostolos Z, Lambrou GI, Nikos M, Patroklos K, Gregory P, Krinio G, et al. New miRNA profiles accurately distinguish renal cell carcinomas and upper tract urothelial carcinomas from the normal kidney. PLoS ONE. 2014;9(3):e91646.CrossRef Apostolos Z, Lambrou GI, Nikos M, Patroklos K, Gregory P, Krinio G, et al. New miRNA profiles accurately distinguish renal cell carcinomas and upper tract urothelial carcinomas from the normal kidney. PLoS ONE. 2014;9(3):e91646.CrossRef
25.
Zurück zum Zitat Enrico M, Luigi M, Apurva C, Masamichi H, Guido M, Matteo B, et al. Clear cell papillary renal cell carcinoma: micro-RNA expression profiling and comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma. J Urol. 2014;191(4):e244-e. Enrico M, Luigi M, Apurva C, Masamichi H, Guido M, Matteo B, et al. Clear cell papillary renal cell carcinoma: micro-RNA expression profiling and comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma. J Urol. 2014;191(4):e244-e.
26.
Zurück zum Zitat Ma Z, Xue S, Zeng B, Qiu D. lncRNA SNHG5 is associated with poor prognosis of bladder cancer and promotes bladder cancer cell proliferation through targeting p27. Oncol Lett. 2018;15(2):1924–30.PubMed Ma Z, Xue S, Zeng B, Qiu D. lncRNA SNHG5 is associated with poor prognosis of bladder cancer and promotes bladder cancer cell proliferation through targeting p27. Oncol Lett. 2018;15(2):1924–30.PubMed
27.
Zurück zum Zitat Wang Z, Pan L, Yu H, Wang Y. The long non-coding RNA SNHG5 regulates gefitinib resistance in lung adenocarcinoma cells by targeting miR-377/CASP1 axis. Biosci Rep. 2018;38(4):BSR20180400.CrossRef Wang Z, Pan L, Yu H, Wang Y. The long non-coding RNA SNHG5 regulates gefitinib resistance in lung adenocarcinoma cells by targeting miR-377/CASP1 axis. Biosci Rep. 2018;38(4):BSR20180400.CrossRef
28.
Zurück zum Zitat Lu Y, Wang S, Yue L, Tognetti L, Rui T, Kang Z, et al. SNHG5 promotes proliferation and induces apoptosis in melanoma by sponging miR-155. RSC Adv. 2018;8(11):6160–8.CrossRef Lu Y, Wang S, Yue L, Tognetti L, Rui T, Kang Z, et al. SNHG5 promotes proliferation and induces apoptosis in melanoma by sponging miR-155. RSC Adv. 2018;8(11):6160–8.CrossRef
29.
Zurück zum Zitat Zhao L, Guo H, Zhou B, Feng J, Li Y, Han T, et al. Long non-coding RNA SNHG5 suppresses gastric cancer progression by trapping MTA2 in the cytosol. Oncogene. 2016;35(44):5770.CrossRef Zhao L, Guo H, Zhou B, Feng J, Li Y, Han T, et al. Long non-coding RNA SNHG5 suppresses gastric cancer progression by trapping MTA2 in the cytosol. Oncogene. 2016;35(44):5770.CrossRef
30.
Zurück zum Zitat Damas ND, Marcatti M, Côme C, Christensen LL, Nielsen MM, Baumgartner R, et al. SNHG5 promotes colorectal cancer cell survival by counteracting STAU1-mediated mRNA destabilization. Nat Commun. 2016;7:13875.CrossRef Damas ND, Marcatti M, Côme C, Christensen LL, Nielsen MM, Baumgartner R, et al. SNHG5 promotes colorectal cancer cell survival by counteracting STAU1-mediated mRNA destabilization. Nat Commun. 2016;7:13875.CrossRef
34.
Zurück zum Zitat Pines J. The cell cycle kinases. Semin Cancer Biol. 1994;5(4):305–13.PubMed Pines J. The cell cycle kinases. Semin Cancer Biol. 1994;5(4):305–13.PubMed
39.
Zurück zum Zitat Bourboulia D, Stetler-Stevenson WG. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion. Semin Cancer Biol. 2010;20(3):161–8.CrossRef Bourboulia D, Stetler-Stevenson WG. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion. Semin Cancer Biol. 2010;20(3):161–8.CrossRef
40.
Zurück zum Zitat Malemud CJ. Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci. 2006;11(2):1696–701.CrossRef Malemud CJ. Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci. 2006;11(2):1696–701.CrossRef
Metadaten
Titel
LncRNA SNHG5 regulates SOX4 expression through competitive binding to miR-489-3p in acute myeloid leukemia
verfasst von
Xiaoyang Ying
Wanggang Zhang
Meiyun Fang
Chenchen Wang
Li Han
Chenmeng Yang
Publikationsdatum
07.04.2020
Verlag
Springer International Publishing
Erschienen in
Inflammation Research / Ausgabe 6/2020
Print ISSN: 1023-3830
Elektronische ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-020-01345-x

Weitere Artikel der Ausgabe 6/2020

Inflammation Research 6/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.